Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.
How this was made

The 30-second read
Why it matters
Earnings beat and milestone payments could trigger short-covering and buying pressure.
Market read
First report of Recursion's earnings beat and milestone revenue, offering actionable insight for biotech traders.
What to watch
High R&D spend and cash burn could limit upside despite earnings beat.
Background
Recursion relies on collaboration revenues; recent Sanofi and Genentech milestones drove Q3 results.
Ticker impact
Recursion reported Q3 2026 earnings beating loss estimates and a $10M milestone from Sanofi, providing fresh financial and clinical data.
likely upward pressure as market prices in the earnings beat and milestone revenue.
Loss per share was narrower than consensus and revenue surged 258% driven by Sanofi payment, indicating improved financial outlook.
Market effects
Positive earnings may lift biotech sector sentiment, especially firms with partnership models.
US biotech investors may see increased buying interest.
Limited to biotech investors; no broad market impact.
Counterpoint
The narrow loss may not translate to revenue growth if milestones are non-recurring.
Key entities
- companyRecursion Pharmaceuticals
Biotech firm reporting Q3 earnings.
- partnerSanofi
Provided $10M milestone payment.



